Atrial Fibrillation Devices Market size to reach $40.2 Bn by 2035

The global atrial fibrillation devices market was valued at USD 12.9 billion in 2025 and is estimated to grow from USD 14.3 billion in 2026 to USD 40.2 billion in 2035, growing at a CAGR of 12.2% from 2026 to 2035, according to the latest report published by Global Market Insights Inc.

High adoption rate of advanced technologies and presence of sophisticated healthcare infrastructure

The widespread adoption of advanced medical technologies, combined with well-established healthcare infrastructure, continues to drive the growth of the atrial fibrillation devices market. Hospitals and specialty cardiac centers are increasingly integrating innovative diagnostic, monitoring, and treatment technologies to improve clinical outcomes and enhance procedural efficiency. Strong availability of skilled healthcare professionals, advanced electrophysiology laboratories, and modern cardiac care facilities further supports the adoption of atrial fibrillation devices.

Increase in prevalence of cardiovascular diseases

The growing incidence of cardiovascular diseases is a major factor fueling demand for atrial fibrillation devices worldwide. Rising cases of hypertension, heart failure, coronary artery disease, obesity, and diabetes are increasing the number of patients at risk of developing atrial fibrillation. As the global population ages and lifestyle-related health conditions become more common, healthcare providers are witnessing greater demand for early diagnosis, continuous cardiac monitoring, and advanced treatment options.

High cost associated with atrial fibrillation devices

The high cost of atrial fibrillation devices remains a significant challenge limiting broader market adoption, particularly in cost-sensitive healthcare systems. Advanced diagnostic systems, catheter ablation technologies, implantable monitoring devices, and associated procedural expenses require substantial financial investment from healthcare providers and patients. In addition, ongoing maintenance, specialized training, and follow-up care further increase the overall cost of treatment.

Browse key industry insights spread across pages and market data tables and figures from the report, “Atrial Fibrillation Devices Market Size, Market, By Product (EP ablation catheter, Radiofrequency (RF), Laser, Cryoablation, Ultrasound, Microwave, Other EP ablation catheters),  Cardiac monitors or implantable loop recorder, EP diagnostic catheters (Advanced mapping catheters, Steerable catheters, Fixed curve catheters), Mapping and recording systems, Access devices, Intracardiac echocardiography (ICE), Left atrial appendage (LAA) closure devices, Other products,  By End Use (Hospitals, Cardiac centers, Ambulatory surgical centers, Other end-users)” in detail, along with the table of contents:  

https://www.gminsights.com/industry-analysis/atrial-fibrillation-devices-market

EP Ablation Catheters to Gain Traction

The EP ablation catheters segment held a 30.6% share in 2025, driven by its essential role in catheter-based ablation procedures used to treat atrial fibrillation and other cardiac rhythm disorders. Continuous technological advancements, including improved contact force sensing, enhanced irrigated tip designs, and more efficient energy delivery systems, strengthened the safety and effectiveness of ablation procedures.

Rising Demand Among Hospitals

The hospitals segment held around 43.7% share of atrial fibrillation devices market in 2025 and is projected to reach USD 17.8 billion during 2026-2035. Rising demand for specialized hospital-based centers dedicated to the diagnosis, treatment, and management of atrial fibrillation encouraged greater investment in advanced AF devices. Hospitals expanded procurement of diagnostic, therapeutic, and patient monitoring technologies to support comprehensive cardiac care.

North America to Propel Market Growth

North America atrial fibrillation devices market accounted for a 40.6% share in 2025. The region experienced a high prevalence of atrial fibrillation due to the growing aging population, increasing rates of obesity, hypertension, diabetes, and other cardiovascular conditions. The expanding patient population generated strong demand for advanced diagnostic and treatment devices designed to manage atrial fibrillation effectively. High healthcare expenditure across the region also supported substantial investments in innovative medical technologies, enabling wider adoption of advanced atrial fibrillation devices and reinforcing North America's leadership in the global market.

Major companies operating in the global atrial fibrillation devices market include Abbott, Acutus Medical, AtriCure, Biotronik, Boston Scientific Corporation, CardioFocus, CathRx, Hansen Medical, Imricor, Johnson & Johnson, Medtronic, MicroPort Scientific Corporation, OSYPKA MEDICAL, Stryker Corporation, and Synaptic Medical.

Companies operating in the atrial fibrillation devices market strengthened their market position by investing heavily in research and development to introduce innovative technologies that improved procedural accuracy, safety, and clinical outcomes. Manufacturers expanded their product portfolios by developing advanced ablation systems, mapping technologies, and cardiac monitoring devices that addressed evolving physician and patient needs.

In June 2026, Medtronic launched the PulseSelect system in India to treat atrial fibrillation (AFib), the most common cardiac rhythm disorder associated with an increased risk of stroke.